drugset / Trial / NCT01429987

The Plecanatide Chronic Idiopathic Constipation (CIC) Study

NCT01429987

Phase 2/3 Completed 951 enrolled Bausch Health Americas, Inc. Parexel · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).

Timeline

Start
2011-10
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Plecanatide Peptide 0.3 mg Oral
Subject Plecanatide Peptide 1 mg Oral
Subject Plecanatide Peptide 3 mg Oral

Indications